Trastzumab Deruxtecan

Phase 2Antibody–drug conjugate

YYonsei University

Trastzumab Deruxtecan is one of 4 small molecule programs targeting PARP Inhibitor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PARP InhibitorNot yet recruiting

PARP InhibitorPhase 2

Not yet recruiting

Competition

Competitive Landscape

3 competitors in PARP Inhibitor

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Phase 2

4 2

Avastin

Roche

Phase 2

1 3

Talzenna

Pfizer

Phase 1

1 4

Trastzumab Deruxtecan

YYonsei University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Not yet recruiting

PARP Inhibitor

NCT07340164

Clinical

Trials by Indication[1]

PARP Inhibitor1 trial

Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy

Not yet recruiting·YYonsei University·Phase 2·NCT07340164·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Trastzumab Deruxtecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Trastzumab Deruxtecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Trastzumab Deruxtecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: YYonsei University

Trastzumab Deruxtecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

PARP Inhibitor1 trial

References

Drug Info

Quick Facts

Related News